BackOxford-AstraZeneca COVID-19 vaccine: 'Review on, no conclusion yet,' says EMA on blood clot cases
The EMA's safety committee 'has not yet reached a conclusion and the review is currently ongoing', the agency said in a statement
PremiumThe European Medicines Agency said Tuesday it is still deciding whether the AstraZeneca vaccine causes blood clots, after a top official said in an interview that there was a clear link.
The EMA's safety committee "has not yet reached a conclusion and the review is currently ongoing", the agency said in a statement to AFP, adding that it expected to announce a decision on Wednesday or Thursday.
Earlier a senior official for the European Medicines Agency (EMA) said in an interview published on Tuesday said that there is a link between AstraZeneca's COVID-19 vaccine and very rare blood clots in the brain but the possible causes are still unknown,
"In my opinion we can now say it, it is clear that there is an association with the vaccine. However, we still do not know what causes this reaction," Marco Cavaleri, chair of the vaccine evaluation team at the EMA, told Italian daily Il Messaggero when asked about the possible relation between the AstraZeneca shot and cases of brain blood clots.
Cavaleri added that the EMA would say there is a link although the regulator would not likely be in a position this week to give an indication regarding the age of individuals to whom the AstraZeneca shot should be given.
He did not provide evidence to support his comments.
The regulator has consistently said the benefits outweigh the risks as it investigates 44 reports of an extremely rare brain clotting ailment known as cerebral venous sinus thrombosis (CVST) out of 9.2 million people in the European Economic Area who have received the AstraZeneca vaccine.
The World Health Organization has also backed the vaccine.
The EMA said last week that its review had at present not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders, for these very rare events. A causal link with the vaccine is not proven, but is possible and further analysis is continuing, the agency said.
A high proportion among the reported cases affected young and middle-aged women but that did not lead EMA to conclude this cohort was particularly at risk from AstraZeneca's shot.
The EMA is expected to give an update of its investigation on Wednesday.
Some countries, including France, Germany and the Netherlands, have suspending the use of the vaccine in younger people while the investigations continue.
Scientists are exploring several possibilities that might explain the extremely rare brain blood clots that occurred in individuals in the days and weeks after receiving the AstraZeneca vaccine.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!
